Global Parkinson's Disease Drugs Market Outlook 2022 – Research


The “Global Parkinson’s Disease Drugs Market Outlook 2022” report has been added to Research and Markets’ offering.

Global Parkinson’s Disease Drugs Market Outlook 2022, the global Parkinson’s disease drugs market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global Parkinson’s disease drugs market. The report provides insight about the major drivers, such as increasing awareness about Parkinson’s disease and its treatment options, research grants and funds, for the global Parkinson’s disease drugs market.

Furthermore, few challenges, such as patent expiry and high cost of treatment, which are hindering the growth of the global Parkinson’s disease drugs market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global Parkinson’s disease drugs market.

The global Parkinson’s disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine therapy, MAO-B inhibitor therapy, COMT inhibitor therapy, and other types of therapies. Among all the types, levodopa therapy is the first and most potent treatment for the Parkinson’s disease. The benefits of the medication are witnessed soon after administration.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Parkinson’s Disease: An Overview

4. Market Dynamics

4.1 Drivers

4.1.1 Increasing Funding Support & Research Grants

4.1.2 Increasing Awareness

4.1.3 Rising Healthcare Expenditure

4.1.4 Increasing Life Expectancy

4.2 Challenges

4.2.1 Patent Expiry of Blockbuster Drugs

4.2.2 High Cost of Treatment

4.2.3 Side Effects of Parkinson’s Disease Drugs

4.3 Opportunities

4.3.1 Collaborations with Academic Institutions for Developing Innovative Solutions

4.3.2 Reduction in Off Time to Improve Patient and Economic Outcomes

4.3.3 Growing Geriatric Population

5. Global Parkinson’s Disease Drugs Market Outlook 2022

6. Major Products in Parkinson’s Disease Market

6.1 Duodopa/Duopa

6.2 Azilect

6.3 Mirapex/Mirapex ER

6.4 Requip

6.5 Neupro

6.6 Rytary/Numient

6.7 Xadago

6.8 Nuplazid

7. Market Segmentation by Type of Therapy

7.1 Levodopa Therapy

7.2 Dopamine Agonist Therapy

7.3 MAO-B Inhibitor Therapy

7.4 COMT Inhibitor Therapy

7.5 Other Therapy

8. Market Segmentation by Geography

8.1 North America

8.2 Europe

8.3 Asia-Pacific

9. Trends & Developments

9.1 Stem Cell Therapies – Revolutionizing Parkinson Treatment

9.2 Incessant Launch of Novel Products

10. Mergers & Acquisitions

11. Drugs Pipeline of Parkinson’s Disease

12. Company Profiles

12.1 Abbvie Inc.

12.2 Newron Pharmaceuticals SpA

12.3 Acadia Pharmaceuticals Inc.

12.4 Boehringer Ingelheim International GmbH

12.5 Teva Pharmaceutical Industries Limited

12.6 GlaxoSmithKline plc

12.7 UCB S.A.

12.8 Novartis AG

12.9 Impax Laboratories, Inc.

12.10 Valeant Pharmaceuticals International, Inc.

12.11 Merck & Co., Inc.

12.12 Mylan N.V.

12.13 F. Hoffmann-La Roche Ltd.

12.14 US WorldMeds, LLC

For more information about this report visit

Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Copyright Business Wire 2017

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and have questions or removal requests please contact

Read more

Leave A Comment

Your email address will not be published. Required fields are marked *